The common characteristic of polycystic ovary syndrome (PCOS) is a disturbance in the selection of the dominant follicle, resulting in anovulation. In PCOS women, serum anti-Mü llerian hormone (AMH) levels are elevated. Because AMH decreases FSH sensitivity in mice, the elevated AMH levels may contribute to the disturbed follicle selection in PCOS women.
onstrated, i.e. the heritability estimate in monozygotic twin sisters is 0.72 (3) , and a candidate gene approach has been widely used to identify the molecular genetic mechanisms and the metabolic and/or biochemical pathways that are implicated in the etiology of PCOS (4). In particular, candidate genes involved in pathways that regulate gonadotropin secretion, affect androgen production and action, and influence insulin signaling have been considered (reviewed in Refs. 4 and 5) . However, little is known about factors involved in early follicle development (6) . An important regulator of folliculogenesis that may play a role in the pathophysiology of PCOS is anti-Mü llerian hormone (AMH), also known as Mü llerian inhibiting substance (7) . AMH is produced by the granulosa cells of growing follicles in the ovary, and serum AMH levels correlate with the number of antral follicles as observed by transvaginal ultrasound (8) . PCOS women display a 2-to 3-fold increase in serum AMH levels, compared with normoovulatory women, reflecting the increased number of small antral follicles (9, 10) .
Although little is known about the role of AMH in the human ovary, studies in mice showed that AMH inhibits initial recruitment (11) and reduces FSH sensitivity of growing follicles (12) . Given its comparable expression pattern in women and mice (13, 14) , AMH may have similar roles in human ovarian folliculogenesis. Hence, the high AMH levels in women with PCOS may contribute to their aberrant follicle selection. Because AMH inhibits FSH-induced aromatase activity in in vitro cultured mouse (15) and human granulosa cells (16) , AMH may also be responsible for the reduced aromatase activity in PCOS granulosa cells (7, 17) and contribute to the elevated androgen levels in PCOS women. Indeed, AMH serum levels are positively correlated with androgen levels in PCOS patients (9, 10) , supporting the latter hypothesis.
Recently we showed that two genetic variants of AMH (Ile 49 Ser; rs10407022) and its specific type II receptor (AMHR2 Ϫ482 AϾG; rs2002555) genes are associated with estradiol levels in normoovulatory women, suggesting that these polymorphisms modulate intraovarian FSH sensitivity and thereby aromatase activity (18) . In this study, we investigated for the first time whether these genetic variants of the AMH signaling pathway are associated with the susceptibility or phenotype of PCOS in a large Dutch Caucasian cohort of PCOS women (n ϭ 331). In addition, in vitro studies were performed to analyze the functional aspects of the AMH Ile 49 Ser polymorphism.
Subjects and Methods

Subjects
The local Medical Ethics Review Committee approved of this study, and informed consent was obtained from all participants. Dutch Caucasian patients attending our fertility clinic between 1993 and 2004, who fulfilled the definition of PCOS according to the Rotterdam criteria (2) were enrolled in this study (n ϭ 407). Hyperandrogenism was defined as elevated (Ͼ4.5) free androgen index (testosterone ϫ 100/SHBG). Polycystic ovaries were defined as 12 or more follicles (measuring 2-9 mm) per ovary, and the ovarian volume was considered to be increased above 10 ml (19) . Standardized initial screening (clinical investigation, transvaginal ultrasound, and fasting blood withdrawal) was performed on a random cycle day between 0900 and 1100 h, irrespective of the interval between blood sampling and the preceding menses.
DNA was available of 394 PCOS women, and genotyping for the AMH and AMHR2 polymorphisms was successful in 385 women. In a subset of 331 women, AMH serum levels and ultrasound data were available.
For sonographic imaging, we used a 6.5-MHz vaginal transducer (model EUB-415; Hitachi Medical Corp., Tokyo, Japan). Ovarian volume and follicle number were assessed as described earlier (20) . Serum hormone levels were assessed at the time patients were originally seen using the following assays: serum FSH, LH, and SHBG were measured by luminescence-based immunometric assays (Immulite 2000; Diagnostic Products Corp., Los Angeles, CA). Serum estradiol and testosterone were measured using RIAs (Diagnostic Products Corp.). Serum androstenedione was measured using the Immulite 2000. Inhibin B was measured using an enzyme-immunometric assay (Oxford BioInnovation, Oxford, UK). AMH levels were measured collectively in samples stored frozen using an in-house AMH ELISA (21), commercially available through Diagnostic Systems Laboratories (Webster, TX). We have previously shown that AMH immunoreactivity in serum is stable during storage and after repeated freeze thaw cycles (21) . Intra-and interassay coefficients of variation were less than 3 and 5.8% for FSH, less than 3.5 and 7.1% for LH, less than 10.9 and 10.7% for androstenedione, less than 6.0 and 4.8% for SHBG, less than 10.2 and 8.8% for estradiol, less than 5.7 and 8.4% for testosterone, less than 7.0 and 15% for inhibin B, and less than 3.5 and 4% for AMH. Free testosterone levels were calculated using the equation according to Sodergard et al. (22, 23) .
The control group consisted of 32 Dutch Caucasian normoovulatory women in whom the AMH and AMHR2 polymorphism were genotyped, as described previously (18) . Inclusion criteria were a regular menstrual cycle (26 -30 d) , age between 20 and 36 yr, and normal body mass index (BMI) (18 -25 kg/m 2 ). Serum testosterone, serum AMH, and follicle number were assessed on d 3 of the menstrual cycle using the methods described above.
In addition, a large population-based cohort of the elderly, the Rotterdam study, was used to determine the allele and genotype frequency of the AMH and AMHR2 polymorphisms in the general Dutch Caucasian population. The design and rationale of this study have been described earlier (24) . For the present study, only women were included (n ϭ 3635).
Furthermore, allele frequencies of the AMH and AMHR2 polymorphisms in the PCOS group were compared with frequencies reported for Caucasians in the HapMap database (www.hapmap.org) (25) .
Genotyping
Genomic DNA was extracted from peripheral blood using standard DNA extraction methods. Previously we have shown that the AMH Ile 49 Ser and AMHR2 Ϫ482 AϾG polymorphism are both in complete linkage disequilibrium (DЈ ϭ 1 and r 2 ϭ 1) with additional polymorphisms with an allele frequency greater than 10% located in the coding and noncoding regions of each gene, including 1 kb of the promoter region (18) . The AMH Ile 49 Ser and AMHR2 Ϫ482 AϾG genotypes were determined using Taqman allelic discrimination assays. For the AMH Ile 49 Ser polymorphism, an Assay-by-Design (Applied Biosystems, Nieuwerkerk aan den IJssel, The Netherlands) with the following probes was used: 5Ј-CTCCAGGCAtCCCACAA-3Ј and 5Ј-CCAGGCAgCCCA-CAA-3Ј. For the AMHR2 Ϫ482 AϾG promoter single-nucleotide polymorphism, we used an Assay-on-Demand, Assay (ID C_1673084_10). Reactions were performed as described previously (18) .
Recombinant human AMH (hAMH) production
The full-length hAMH cDNA was isolated from human testis and subcloned into the pcDNA3.1 expression vector (Invitrogen, Breda, The Netherlands) as described previously (14) . Quick-change site-directed mutagenesis was performed according to the manufacturer ( 
Western blot
Western blot analysis was performed using the mouse monoclonal antibodies 5/6A and 9/6A (14, 26) . Proteins from conditioned medium were separated using 12% PAGE under reducing conditions, transferred to nitrocellulose membranes, and incubated with the 5/6A or 9/6A antibody at a 1:1000 dilution, followed by a secondary Alexa Fluor-680 goat antimouse antibody (Molecular Probes, Invitrogen, Breda, The Netherlands) at a 1:15,000 dilution. Proteins were visualized using the Licor-Odyssey imaging system and blots were analyzed with the Odyssey software version 2.1 (LI-COR Biosciences, Westburg, Leusden, The Netherlands).
Cell culture and transfections
The mouse granulosa cell line KK-1 (27) (kind gift from Dr. I. Huhtaniemi, Institute of Reproduction and Developmental Biology, Imperial College of London, London, UK), and the human granulosa cell line COV434, derived from a human granulosa cell tumor but possessing many characteristics of normal granulosa cells (28, 29) , were cultured in DMEM/F12 (Life Technologies, Inc., Invitrogen, Breda, The Netherlands) containing 10% fetal calf serum and penicillin (400 IU/ml) and streptomycin (0.4 mg/ml), and stably transfected with an AMHRII expression vector (30) . For AMH-induced luciferase assays, KK-1 and COV434 cells were seeded at 20% confluency in 24-well plates and transfected with the BRE-Luc reporter plasmid (150 ng/well) (31) (kind gift from Dr. P. ten Dijke, Department of Molecular Cell Biology, Leiden University Medical Center, Leiden, The Netherlands) using Fugene 6 transfection reagent (Roche Diagnostics, Almere, The Netherlands) The pRL-TK plasmid (Promega, Leiden, The Netherlands) served as an internal control to normalize for transfection efficiency. Twenty-four hours after transfection, cells were cultured for 2 h in medium containing 0.2% fetal calf serum followed by 16 h treatment with increasing concentrations of the hAMH variants. Luciferase activity was determined using the Dual-Glo luciferase assay (Promega) in the TOPCOUNT luminometer (Applied Biosystems).
Statistical analysis
AMH levels were compared between normoovulatory controls and PCOS women using one-way analysis of (co)variance, with adjustment for age and BMI. Within the PCOS cohort, Spearman's correlation coefficient was used to correlate AMH serum levels with additional hormone levels and total follicle number.
In each group of women, genotype frequencies of the AMH and AMHR2 polymorphisms were tested for Hardy-Weinberg equilibrium proportions using the ARLEQUIN package (32) . Differences in allele and genotype frequencies between cases and controls were tested using a 2 test. For reasons of statistical power, carriers of the AMH 49 Ser allele and carriers of the AMHR2 Ϫ482G allele were compared with noncarriers. If appropriate, hormone levels were log transformed to normalize their distribution. Within the PCOS group, one-way analysis of (co)variance was used to determine differences in continuous variables between genotype groups. Androgen-related traits and ovarian parameters were adjusted for age and BMI. Categorical parameters were analyzed using Fisher's exact test. Subsequently, to correct for multiple testing, we obtained an empirical P value by permutation analysis using Haploview version 3.32 (33) . The phenotypic status of each individual was permuted 10,000 times and association analysis was performed to obtain the test statistic under the null hypothesis of no association. The empirical P value was obtained as the proportion of the 10,000 replicates that had a P value less than or equal to the one obtained from the actual (unshuffled) data.
Prism software was used to fit the sigmoidal dose-response curves of the in vitro studies and to calculate the EC 50 and maximal response values. To test differences in EC 50 and maximal response between the AMH variants, the F test comparison method was used (GraphPad Prism 4.0 Software, GraphPad Inc., San Diego, CA).
Unless stated otherwise, analyses were performed using Statistical Package for Social Sciences, SPSS, version 11.0.1 (SPSS Inc., Chicago, IL). P Յ 0.05 was considered to be significant.
Results
AMH serum levels in PCOS women
Clinical characteristics of the normoovulatory women and the PCOS women are shown in Table 1 . As shown previously, PCOS patients had elevated AMH levels, compared with normoovulatory controls (Table 1) . To provide insight into the relationship of AMH serum levels with androgen levels and follicle number in the PCOS cohort, correlation coefficients between AMH levels and these parameters were determined. In the PCOS cohort, serum AMH levels were positively correlated with total testosterone levels (r ϭ 0.44, P Ͻ 0.001), free testosterone levels (r ϭ 0.36, P Ͻ 0.001), androstenedione levels (r ϭ 0.44, P Ͻ 0.001), LH levels (r ϭ 0.31, P Ͻ 0.001), and total follicle number (r ϭ 0.54, P Ͻ 0.001) but not with estradiol levels (r ϭ 0.01, P ϭ 0.80). 
PCOS risk by AMH and AMHR2 genotypes
Genotype and allele frequencies of the AMH Ile 49 Ser and the AMHR2 Ϫ482 AϾG polymorphism in the 331 PCOS women did not differ from frequencies in the normoovulatory controls and the (postmenopausal) women of the Rotterdam study ( Table  2 ). In addition, the allele frequencies for both polymorphisms in PCOS women were similar to allele frequencies of Caucasians in the HapMap database (www.hapmap.org) (25 (Table 3) . However, carriers of the AMH 49 Ser allele had polycystic ovaries less often, compared with noncarriers (92.7 vs. 99.5%, P ϭ 0.0008), which remained significant after permutation analysis (P ϭ 0.0004) ( Table 3) . Hence, 49 Ser allele carriers also had a lower total follicle number, on average 5.4 follicles less (12%), compared with noncarriers (P ϭ 0.03) ( Table 3 ). The mean ovarian volume and the percentages of women with amenorrhea were not different between both genotype groups (Table 3) .
AMH levels were similar between carriers and noncarriers of the AMH 49 Ser allele, but AMH 49 Ser allele carriers had almost 10% lower total testosterone (P ϭ 0.05) and androstenedione levels (P ϭ 0.04), compared with noncarriers (Table 4) . However, SHBG levels were also lower in AMH 49 Ser allele carriers, compared with noncarriers (P ϭ 0.04), and hence, free testosterone levels were not significantly different between the AMH genotype groups (P ϭ 0.17). FSH, LH, estradiol, and inhibin B levels were similar in both groups (Table 4 ).
Functional analysis of the AMH Ile
49 Ser polymorphism The results described above suggest that the AMH Ile 49 Ser polymorphism modulates AMH function. To determine whether this polymorphism had an effect on secretion and/or processing of AMH, Western blot analysis of supernatants from hAMH- 49 Ile and hAMH- 49 Ser expressing cells was performed using proregion-specific (Mab 9/6A) and mature region-specific (Mab 5/6A) antibodies. For both AMH variants, the N-terminal proregion, the C-terminal mature region and an additional cleavage band as a result of a potential second cleavage site were detected with comparable intensities (Fig. 1) , suggesting similar processing. The observed incomplete processing of recombinant hAMH- 49 Ile and hAMH-49 Ser is consistent with previous reports (34, 35) . Introduction of an optimized cleavage site (RARR) resulted in fully cleaved AMH. Again, no differences in processing between hAMH-RARR- 49 Ile and hAMH-RARR-49 Ser were observed (results not shown).
To determine the effect of the Ile 49 Ser polymorphism on AMH bioactivity, a mouse granulosa cell line (KK-1) and a human granulosa cell line (COV434) were transiently transfected with the AMH-responsive luciferase reporter BRE-Luc and stimulated with hAMH- 49 Ile and hAMH-49 Ser. Dose-response experiments in both cell lines revealed that stimulation with equal amounts of hAMH-49 Ser resulted in a similar EC 50 but a significantly lower maximal induction of luciferase activity, compared with stimulation with hAMH-49 Ile (P Ͻ 0.0001) (Fig. 2, and results not shown) . These observations suggest that the hAMH- 49 Ser constitutes an AMH protein with lower bioactivity.
PCOS phenotype by AMHR2 -482 A>G genotype
The AMHR2 Ϫ482 AϾG polymorphism was not associated with age, BMI, and waist hip ratio (Table 3) . Furthermore, no association of the AMHR2 genotypes with polycystic ovaries, follicle number, or ovarian volume was observed (Table 3) . AMH serum levels, androgen levels, and other hormones also did not differ between the genotype groups ( Table 4) .
Discussion
The present study was designed to investigate the functional role of AMH in PCOS using a genetic approach. The association of polymorphisms in genes of the AMH signaling pathway with PCOS susceptibility and phenotype was studied in a large cohort of PCOS women. We observed that polymorphisms in the AMH and AMHR2 gene did not contribute to the risk for PCOS. However, within the PCOS group, the AMH Ile 49 Ser polymorphism was associated with follicle number, androgen levels, and percentage of women exhibiting polycystic ovaries.
The main feature of follicular dysfunction in PCOS is the disturbed selection of the dominant follicle resulting in anovulation. Studies in mice have shown that AMH decreases FSH sensitivity in vivo and in vitro (12) . Hence, the elevated AMH levels in PCOS women may contribute to the refractoriness to FSH-induced follicle differentiation, leading to the aberrant selection process. Although the etiology of PCOS is not clearly established, accumulating evidence suggests that PCOS results primarily from exposure of the fetal ovary to high androgen levels (37) . Subsequently secondary genetic and environmental factors may interact with this underlying process and lead to the heterogeneity in the phenotype of PCOS (38) The AMHR2 Ϫ482 AϾG polymorphism is associated with neither PCOS susceptibility nor the final phenotype. Although we observed in our previous study that the AMHR2 Ϫ482G allele was associated with higher follicular phase estradiol levels in premenopausal women, suggesting less inhibition of FSHsensitivity by this AMHR2 variant (18) , in PCOS women this effect may be masked by the elevated AMH levels.
Candidate gene studies in PCOS suffer from a lack of reproducibility between cohorts, which may be attributed to the different criteria used to define PCOS but also to several additional factors (4). First, most PCOS studies reported so far have been based on very small sample sizes, therefore lacking sufficient statistical power. In contrast, our cohort, which consists of 331 PCOS women, is among the largest studied in PCOS genetics. Second, in many studies only one or a few variants per gene have been tested, whereas it is critical to characterize the genetic variation of the entire candidate gene to unravel the etiology of genetically complex diseases such as PCOS (4). In our study, the analyzed polymorphisms in the AMH and AMHR2 gene both capture the common genetic variation in the gene, including 1 kb of the promoter region (18) . Last but not least, the issue of multiple testing requires attention in association studies. Nevertheless, the association of the AMH Ile 49 Ser polymorphism with the PCO phenotype withstands correction for multiple testing using permutation analysis. In addition, the strong a priori rationale in combination with the functional evidence makes it very unlikely that our results could be explained by chance alone (41) .
In conclusion, our results provide new insight into the role of AMH in the pathophysiology of PCOS. The observed association between the AMH Ile 49 Ser polymorphism and follicle number and androgen levels, together with the in vitro evidence of the functional effect of this polymorphism, strongly suggests that AMH contributes to the severity of the PCOS phenotype. Although the findings of the association study need to be replicated in additional cohorts, our results imply that the AMH Ile 49 Ser polymorphism is one of the genetic factors contributing to the complex etiology of PCOS.
